Myelodysplastic Syndrome (MDS) Gastrointestinal (GI) Tolerability Study
| Status: | Completed |
|---|---|
| Conditions: | Blood Cancer, Hematology |
| Therapuetic Areas: | Hematology, Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 11/18/2012 |
| Start Date: | December 2011 |
| End Date: | March 2013 |
| Contact: | Novartis Pharmaceuticals |
| Phone: | +1(800)340-6843 |
A Multicenter, Randomized, Comparative Study of Different Deferasirox Administration Regimens on Gastrointestinal (GI) Tolerability in Low or Intermediate (Int-1) Risk MDS Myelodysplastic Syndrome Patients With Transfusional Iron Overload.
The objective of the study is to evaluate and compare the frequency and severity of GI
adverse events in different dose administration regimens. The patient population consists of
low or intermediate (int-1) risk myelodysplastic syndrome (MDS) patients with transfusional
iron overload. The study patients are randomized to either a morning dose of 20 mg/kg/day
deferasirox or an evening dose of the same. Patients are then followed up for 6 months for
any GI events and are assessed using patient reported outcomes tools e.g. a patient diary.
Inclusion Criteria:
- Written informed consent prior to any screening procedures
- Male or female patients ≥ 18 years of age
- Patient must weigh between 45-135 kg
- Patients with low or intermediate (int-1) risk MDS, as determined by IPSS score or
RA, RARS by WHO criteria. IPSS must be confirmed by a bone marrow examination within
6 months prior to study entry and must be hematologically stable
Deferasirox naïve:
Sexually active pre-menopausal female patients must use double-barrier contraception, oral
contraceptive plus barrier contraceptive, or must have undergone clinically documented
total hysterectomy and/or oophorectomy, tubal ligation
Exclusion Criteria:
- History or current GI disease
- Systemic diseases which could prevent study treatments
- Left ventricular ejection fraction< 50 % by echo cardiography
- Serum creatinine > 1.2 x ULN at screening
- Platelet counts < 25x 109/L except in cases where guidance is already given in the
local deferasirox label
- AST or ALT > 2.5 xULN at screening
Other protocol-defined inclusion/exclusion criteria may apply
We found this trial at
3
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials